Statin-induced Myopathy: Hypothesis About Randomized Evidence and Clinical Impressions - 12/08/11
Doi : 10.1016/j.amjmed.2008.06.043
Le texte complet de cet article est disponible en PDF.
| Conflict of Interest: This article poses no conflicts of interest for the author. The work is original and the author meets the criteria for authorship, including acceptance of responsibility for the scientific content and writing of the article. The author's financial affiliations with all organizations, including any with a financial interest, direct or indirect, in the subject matter or materials discussed in the article that may affect the conduct or reporting of the work submitted are listed below: |
|
| The author serves as an independent scientist in an advisory role to investigators and sponsors, including as Chair or Member on Data and Safety Monitoring Boards, for AstraZeneca, Bristol-Myers Squibb, Food and Drug Administration, Merck, National Association for Continuing Education, National Institutes of Health, Pfizer, PriMed and UpToDate. The author serves on speakers' bureaus for the International Atherosclerosis Society and AstraZeneca, concerning lipids and heart failure, as well as Pfizer, concerning lipids. |
|
| The author receives royalties for authorship or editorship of 3 textbooks. |
|
| The author receives royalties as co-inventor on patents concerning inflammatory markers and cardiovascular disease, which are held by Brigham and Women's Hospital. |
|
| The author has an investment management relationship with SunTrust Bank, who has sole discretionary investment authority. |
© 2009
Publié par Elsevier Masson SAS.
Vol 122 - N° 1
P. 4-5 - janvier 2009 Retour au numéro
Article précédent
- Should a Hand-carried Ultrasound Machine Become Standard Equipment for Every Internist?
- Joseph S. Alpert, Jeanette Mladenovic, David B. Hellmann
- Asthma in Seniors: Part 1. Evidence for Underdiagnosis, Undertreatment, and Increasing Morbidity and Mortality
- Eric Stupka, Richard deShazo
Déjà abonné à cette revue ?